Adalimumab originator versus adalimumab biosimilars in inflammatory bowel disease in Australia
Volume 23, Issue 8, July - December 2023 .
Source: Expert Opinion on Biological Therapy - Category: Drugs & Pharmacology Authors: Emilia AndersonKaren WallerAravind Gokul TamilarasanHuiyu LinSudarshan ParamsothyRupert W Leonga Department of Gastroenterology and Hepatology, Concord Repatriation General Hospital, Sydney, NSW, Australiab Faculty of Medicine and Health, Concord Clinical Source Type: research
More News: Australia Health | Drugs & Pharmacology | Gastroenterology | Hospitals | Humira | Inflammatory Bowel Disease